Web of Science:
One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study

dc.contributor.authorYozgat, Z.
dc.contributor.authorIsik, M.U.
dc.contributor.authorSabaner, M.C.
dc.date.accessioned2024-12-02T10:40:05Z
dc.date.available2024-12-02T10:40:05Z
dc.date.issued2024.01.01
dc.description.abstractIntroductionThe aim of this study was to compare the efficacy of the treat-and-extend (TAE) regimen versus the pro re nata (PRN) regimen in patients with bevacizumab-resistant diabetic macular edema (DME) treated with aflibercept, with or without adjunctive laser therapy.MethodsNinety-one eyes from 91 patients who were switched to aflibercept after three consecutive intravitreal bevacizumab injections for the treatment of DME were included in this retrospective real-world study. The patients were categorized into three groups: TAE (n = 30), TAE + laser (n = 31), and PRN (n = 30). Changes in best-corrected visual acuity and central macular subfield thickness (CMST) at 12, 24, and 52 weeks were defined as the primary functional and anatomical outcomes.ResultsA total of 91 eyes from 91 patients (49.5% female) with a mean age of 63.9 +/- 7.1 years were included in the analysis. At 52 weeks, the mean letter gains were 8.03, 8.90, and 10.23 in the TAE, TAE + laser, and PRN groups, respectively. Anatomical improvements, as measured by CMST reduction, were 55.33 mu m, 33.35 mu m, and 48.96 mu m in the TAE, TAE + laser, and PRN groups, respectively. The average number of injections administered was 7.7, 8.1, and 8.1, respectively. The final extension interval for the TAE group was 8.7 weeks, compared to 9.5 weeks in the TAE + laser group.ConclusionsThe PRN group demonstrated the highest functional improvement while the TAE group showed the greatest anatomical improvement. Overall, both anatomical and functional outcomes in the TAE regimen were comparable to the PRN regimen in patients with bevacizumab-resistant diabetic macular edema.
dc.identifier.doi10.1007/s40123-024-01067-x
dc.identifier.eissn2193-6528
dc.identifier.endpage
dc.identifier.issn2193-8245
dc.identifier.issue
dc.identifier.startpage
dc.identifier.urihttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=dspace_ku&SrcAuth=WosAPI&KeyUT=WOS:001361126400001&DestLinkType=FullRecord&DestApp=WOS_CPL
dc.identifier.urihttps://hdl.handle.net/20.500.12597/33822
dc.identifier.volume
dc.identifier.wos001361126400001
dc.language.isoen
dc.relation.ispartofOPHTHALMOLOGY AND THERAPY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAflibercept
dc.subjectBevacizumab-resistant
dc.subjectDiabetic macular edema
dc.subjectPro re nata regimen
dc.subjectReal-world study
dc.subjectTreat-and-extend regimen
dc.titleOne-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study
dc.typeArticle
dspace.entity.typeWos

Files